The TSP motif in AP180 inhibits phospholipase D1 activity resulting in increased efficacy of anticancer drug via its direct binding to carboxyl terminal of phospholipase D1

Cancer Letters

Volumn 302, Issue 2, 2011, Pages 144-154

  Cho, Ju Hwan ^a   Oh, Doo Yi ^a   Kim, Hyoung Ju ^a   Park, Shin Young ^a   Choi, Hye Jin ^a   Kwon, Sung Joon ^a   Lee, Ki Sung ^b   Han, Joong Soo ^a  

^a Hanyang University   (South Korea)

^b PaiChai University   (South Korea)

Author keywords

Assembly protein 180; Cancer; Peptidomimetic drug; Phospholipase D1; Site directed mutagenesis

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PROTEIN; DOCETAXEL; ETOPOSIDE; MUTANT PROTEIN; PHOSPHOLIPASE D1; PROLINE; PROTEIN AP180; SERINE; THREONINE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; GENETIC TRANSFECTION; HUMAN; HUMAN AP180 GENE; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION;

AMINO ACID MOTIFS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MONOMERIC CLATHRIN ASSEMBLY PROTEINS; PHOSPHOLIPASE D; PROTEIN BINDING; SEQUENCE DELETION; STOMACH NEOPLASMS;

EID: 79951580544     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.005     Document Type: Article

References (43)

1. Mendez P., De Roo M., Poglia L., Klauser P., Muller D. N-cadherin mediates plasticity-induced long-term spine stabilization. J. Cell Biol. 2010, 189:589-600.
2. Tsao D.A., Chang H.J., Lin C.Y., Hsiung S.K., Huang S.E., Ho S.Y., Chang M.S., Chiu H.H., Chen Y.F., Cheng T.L., Shiu-Ru L. Gene expression profiles for predicting the efficacy of the anticancer drug 5-fluorouracil in breast cancer. DNA Cell Biol. 2010, 29:285-293.
3. Higashiyama M., Oda K., Okami J., Maeda J., Kodama K., Imamura F., Minamikawa K., Takano T., Kobayashi H. Prediction of chemotherapeutic effect on postoperative recurrence by in vitro anticancer drug sensitivity testing in non-small cell lung cancer patients. Lung Cancer 2010, 68:472-477.
4. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. New Engl. J. Med. 2005, 353:172-187.
5. Stirewalt D.L., Meshinchi S., Kopecky K.J., Fan W., Pogosova-Agadjanyan E.L., Engel J.H., Cronk M.R., Dorcy K.S., McQuary A.R., Hockenbery D., Wood B., Heimfeld S., Radich J.P. Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 2008, 47:8-20.
6. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109:25-32.
7. Press M.F., Lenz H.J. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 2007, 67:2045-2075.
8. Xia W., Spector S., Hardy L., Zhao S., Saluk A., Alemane L., Spector N.L. Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine. Proc. Natl. Acad. Sci. USA 2000, 97:7494-7499.
9. Kleideiter E., Piotrowska K., Klotz U. Screening of telomerase inhibitors. Methods Mol. Biol. 2008, 405:167-180.
10. Martin S.A., Lord C.J., Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Genet. Dev. 2008, 80-86.
11. Shi M., Zheng Y., Garcia A., Xu L., Foster D.A. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. Cancer Lett. 2007, 258:268-275.
12. Kim J., Lee Y.H., Kwon T.K., Chang J.S., Chung K.C., Min D.S. Phospholipase D prevents etoposide-induced apoptosis by inhibiting the expression of early growth response-1 and phosphatase and tensin homologue deleted on chromosome 10. Cancer Res. 2006, 66:784-793.
13. Hui L., Zheng Y., Yan Y., Bargonetti J., Foster D.A. Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene 2006, 25:7305-7310.
14. Cho J.H., Hong S.K., Kim E.Y., Park S.Y., Park C.H., Kim J.M., Kwon O.J., Kwon S.J., Lee K.S., Han J.S. Overexpression of phospholipase D suppresses taxotere-induced cell death in stomach cancer cells. Biochim. Biophys. Acta 2008, 1783:912-923.
15. Hammond S.M., Altshuller Y.M., Sung T.C., Rudge S.A., Rose K., Engebrecht J., Morris A.J., Frohman M.A. Human ADP-ribosylation factor-activated phosphatidylcholine-specific phospholipase D defines a new and highly conserved gene family. J. Biol. Chem. 1995, 270:29640-29643.
16. Colley W.C., Sung T.C., Roll R., Jenco J., Hammond S.M., Altshuller Y., Bar-Sagi D., Morris A.J., Frohman M.A. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr. Biol. 1997, 7:191-201.
17. Chung J.K., Sekiya F., Kang H.S., Lee C., Han J.S., Kim S.R., Bae Y.S., Morris A.J., Rhee S.G. Synaptojanin inhibition of phospholipase D activity by hydrolysis of phosphatidylinositol 4,5-bisphosphate. J. Biol. Chem. 1997, 272:15980-15985.
18. Lee C., Kim S.R., Chung J.K., Frohman M.A., Kilimann M.W., Rhee S.G. Inhibition of phospholipase D by amphiphysins. J. Biol. Chem. 2000, 275:18751-18758.
19. Lee C., Kang H.S., Chung J.K., Sekiya F., Kim J.R., Han J.S., Kim S.R., Bae Y.S., Morris A.J., Rhee S.G. Inhibition of phospholipase D by clathrin assembly protein 3 (AP3). J. Biol. Chem. 1997, 272:15986-15992.
20. Oh J.W., Kim E.Y., Koo B.S., Lee H.B., Lee K.S., Kim Y.S., Han J.S. Der f 2 activates phospholipase D in human T lymphocytes from Dermatophagoides farinae specific allergic individuals: involvement of protein kinase C-alpha. Exp. Mol. Med. 2004, 36:486-492.
21. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
23. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
24. van Blitterswijk W.J., Hilkmann H., de Widt J., van der Bend R.L. Phospholipid metabolism in bradykinin-stimulated human fibroblasts. II. Phosphatidylcholine breakdown by phospholipases C and D; involvement of protein kinase C. J. Biol. Chem. 1991, 266:10344-10350.
25. Ballif B.A., Villen J., Beausoleil S.A., Schwartz D., Gygi S.P. Phosphoproteomic analysis of the developing mouse brain. Mol. Cell. Proteomics 2004, 3:1093-1101.
26. Tweedie-Cullen R.Y., Reck J.M., Mansuy I.M. Comprehensive mapping of post-translational modifications on synaptic, nuclear, and histone proteins in the adult mouse brain. J. Proteome Res. 2009, 8:4966-4982.
27. Ford M.G., Mills I.G., Peter B.J., Vallis Y., Praefcke G.J., Evans P.R., McMahon H.T. Curvature of clathrin-coated pits driven by epsin. Nature 2002, 419:361-366.
28. De Camilli P., Chen H., Hyman J., Panepucci E., Bateman A., Brunger A.T. The ENTH domain. FEBS Lett. 2002, 513:11-18.
29. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J.J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J.L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J.M., Kantarjian H., Taylor K., Verhoef G., Bolton A.E., Capdeville R., Druker B.J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl. J. Med. 2003, 348:994-1004.
30. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl. J. Med. 2002, 347:472-480.
31. Saif M.W., Kang S.P., Chu E. Treatment of metastatic colorectal cancer: from cytotoxic agents to molecular agents and multitargeted strategies. Oncology (Williston Park) 2006, 20:11-19.
32. Schiff P.B., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665-667.
33. Baldwin E.L., Osheroff N. Etoposide, topoisomerase II and cancer. Curr. Med. Chem. Anticancer Agents 2005, 5:363-372.
34. Huang P., Frohman M.A. The potential for phospholipase D as a new therapeutic target. Exp. Opin. Ther. Targets 2007, 11:707-716.
35. Mittelman J.M., Gudkov A.V. Generation of p53 suppressor peptide from the fragment of p53 protein. Somat. Cell. Mol. Genet. 1999, 25:115-128.
36. Kanovsky M., Raffo A., Drew L., Rosal R., Do T., Friedman F.K., Rubinstein P., Visser J., Robinson R., Brandt-Rauf P.W., Michl J., Fine R.L., Pincus M.R. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc. Natl. Acad. Sci. USA 2001, 98:12438-12443.
37. Do T.N., Rosal R.V., Drew L., Raffo A.J., Michl J., Pincus M.R., Friedman F.K., Petrylak D.P., Cassai N., Szmulewicz J., Sidhu G., Fine R.L., Brandt-Rauf P.W. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene 2003, 22:1431-1444.
38. Li Y., Rosal R.V., Brandt-Rauf P.W., Fine R.L. Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide. Biochem. Biophys. Res. Commun. 2002, 298:439-449.
39. Poulaki V., Mitsiades C.S., Joussen A.M., Lappas A., Kirchhof B., Mitsiades N. Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability. Am. J. Pathol. 2002, 161:2229-2240.
40. Thomas R.P., Farrow B.J., Kim S., May M.J., Hellmich M.R., Evers B.M. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery 2002, 132:127-134.
41. Noh D.Y., Ahn S.J., Lee R.A., Park I.A., Kim J.H., Suh P.G., Ryu S.H., Lee K.H., Han J.S. Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett. 2000, 161:207-214.
42. Kang D.W., Min do S. Platelet derived growth factor increases phospholipase D1 but not phospholipase D2 expression via NFkappaB signaling pathway and enhances invasion of breast cancer cells. Cancer Lett. 2010, 294:125-133.
43. Kang D.W., Park M.H., Lee Y.J., Kim H.S., Kwon T.K., Park W.S., Min do S. Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/Ras/ERK/NFkappaB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. J. Biol. Chem. 2008, 283:4094-4104.